Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
Go back to Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes| BANCO SANTANDER S.A. (NYSE: SAN) | Delayed: 14.89 -0.04 (0.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.93 | 52 Week High | $5.58 | |||
| Open | $14.95 | 52 Week Low | $3.60 | |||
| Day High | $14.99 | P/E | N/A | |||
| Day Low | $14.88 | EPS | $0.00 | |||
| Volume | 4,830,110 | |||||
| SANOFI (NASDAQ: SNY) | Delayed: 43.26 -0.98 (2.22%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $44.24 | 52 Week High | $44.76 | |||
| Open | $43.49 | 52 Week Low | $36.81 | |||
| Day High | $43.71 | P/E | N/A | |||
| Day Low | $43.23 | EPS | $0.00 | |||
| Volume | 1,797,610 | |||||
